Frontlight ResearchEarly access
CompletedPhase 1
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
Key facts
- Who runs it
- Miromatrix Medical Inc.
- Where
- Ann Arbor, Chicago, Cleveland, Minneapolis, New York, Richmond, Rochester, and Salt Lake City, United StatesSee the 8 sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 10 people enrolled
- Started
- 5 Oct 2024
- Ended
- 22 Jan 2026
- Type of study
- Interventional
- Treatments tested
- miroliverELAP treatment
- Record updated
- 6 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- 18 years to 80 years old at the time of signing the informed consent
- Subject must:; be deemed competent to consent by an independent qualified practitioner, or; have consent given by a Legally Authorized Representative
- Subject should be in the intensive care unit
- Be diagnosed with 4.1. Acute Liver Failure defined as:; INR ≥ 2.0, and; Hepatic Encephalopathy Grade II-III (West Haven Criteria), and; Less than 4 weeks (28 days) of disease duration 4.2. Severe Acute Alcohol-Associated Hepatitis as defined as:; <!-- -->; Hepatic Encephalopathy Grade I-III (West Haven Criteria), and; Model for End-Stage Liver Disease (MELD) Score ≥ 20, and; INR ≥ 2.0, and; No overt evidence of cirrhosis 4.3. Acute on Chronic Liver Failure:; <!-- -->; Hepatic Encephalopathy Grade I-III (West Haven Criteria), and; Model for End-Stage Liver Disease (MELD) Score ≥ 20, and; INR ≥ 2.0,; Subject is not a candidate for liver transplant and will not become a candidate in the event of worsening conditions
Who cannot take part
- Previous liver transplant
- Currently on medications with a narrow therapeutic index
- Uncontrolled documented infection, hypotension, or refractory shock. This is defined as a need for a single vasopressor, or combination of vasopressors, that exceed a norepinephrine equivalent of 0.5 mcg/kg/min
- Any current liver cancer
- Platelet count < 40,000 μL
- Experiencing a bleeding event, defined as:; Active gastrointestinal or other overt bleeding event, or; Hemoglobin drop > 3g/dL within the past 24 hours, or; Received ≥ 3 units of red blood cell transfusion within the past 24 hours
- Grade IV West Haven Encephalopathy Criteria
- Currently requires chronic hemodialysis (CRRT or other forms of continuous renal replacement are allowed)
- Liver injury due to trauma
- If the subject is intubated and has an acute lung injury
- Female that is currently pregnant, planning to be pregnant, or currently breastfeeding
- Refusal to receive blood products
Where in United States
- University of Michigan Medical SchoolAnn Arbor, United States
- Northwestern Memorial HospitalChicago, United States
- Cleveland Clinic FoundationCleveland, United States
- University of Minnesota Medical SchoolMinneapolis, United States
- Mount Sinai Recanati/Miller Transplantation InstituteNew York, United States
- Virginia Commonwealth University Medical CenterRichmond, United States
- Mayo ClinicRochester, United States
- Intermountain HealthcareSalt Lake City, United States
About the trial
What the trial wants to find out
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.
The group in the trial
- miroliverELAP treatmentTreatment being tested
48 hour treatment with miroliverELAP
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Prospective Study of the Miromatrix External Liver Assist Product (miroliverELAP®) for Liver Support in Adults With Acute Liver Failure.
- Record updated
- 6 March 2026